Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 10/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.50 |
| ▸ | ERN1 | O75460 | 7/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7273581 | 0.89 | ERN1 (0.51) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL28901718 | 0.83 | ERN1 (0.54) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL2428337 | 0.82 | ALDH1A1 (0.42) | ALOX5PTGS2ERN1PPARGPPARA | |
| SCHEMBL27531185 | 0.79 | ALOX5 (0.54) | ALOX5 | |
| SCHEMBL31494239 | 0.79 | ALOX5 (0.46) | ALOX5PTGS2ALDH1A1 | |
| SCHEMBL7536824 | 0.79 | ALOX5 (0.46) | ALOX5PTGS2ALDH1A1 | |
| SCHEMBL2432372 | 0.78 | ALDH1A1 (0.43) | ALOX5ERN1TLR2TLR1TLR6 | |
| SCHEMBL17821776 | 0.78 | ERN1 (0.53) | ERN1TLR2TLR1TLR6 | |
| SCHEMBL9810574 | 0.77 | HIF1A (0.49) | PTGS2ALDH1A1 | |
| SCHEMBL3337249 | 0.77 | ERN1 (0.51) | ERN1TLR2TLR1TLR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363880-A4 | SYNTHESIS FOR THE PREPARATION OF COMPOUNDS FOR SCREENING AS POTENTIAL TUBULIN BINDING AGENTS | UNIV AUSTRALIAN (AU) | 2008-10-08 | — | — | EP | disclosed |
| US-20050130221-A1 | Synthesis for the preparation of compounds for screening as potential tubulin binding agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2005-06-16 | — | — | US | disclosed |
| EP-1363880-A1 | SYNTHESIS FOR THE PREPARATION OF COMPOUNDS FOR SCREENING AS POTENTIAL TUBULIN BINDING AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002060872-A1 | SYNTHESIS FOR THE PREPARATION OF COMPOUNDS FOR SCREENING AS POTENTIAL TUBULIN BINDING AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130221-A1 | Synthesis for the preparation of compounds for screening as potential tubulin binding agents | TUBB, TUBB3, TUBB1 | ALOX5 4816/4885PTGS2 3707/4885ERN1 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.